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In prion disease, a fatal neurodegenerative disorder, the cellular form of the prion protein (PrPC) is 
converted to the disease isoform (PrPSc). Although currently no effective therapies or treatments exist, 
most likely due to the incomplete understanding of prion disease pathogenesis, many studies target 
enhancing PrP clearance or redistribution/sequestration, suppressing PrP expression, or decreasing PrP 
conversion. Some antiprion compounds that have been rigorously tested include 2-aminothiazoles and 
quinacrine. 2-aminothiazoles work by affecting prion conversion or by reducing clearance, while 
quinacrine has its mechanism of action by reducing the protease resistance of PrP aggregates or by 
inhibiting the conversion of PrPC to PrPSc. By combining the effective structures of these two antiprion 
compounds, novel 2-aminothiazole derivatives were synthesized and have been found theoretically to 
have potential anti-prion properties. In this study, we aim to verify the theoretical binding dissociation 
and EC50 values of these compounds and determine whether they are still prion inhibitors in more 
biological systems. Since both 2-aminothiazoles and quinacrine affect prion conversion, perhaps these 
novel compounds exert their inhibitory effect by sequestering PrPC through direct binding or by 
causing an internalization of PrPC in cells so less seed is available for conversion. We used cell toxicity 
assays to determine compound toxicity and surface plasmon resonance (SPR) to detect binding 
affinities. Confocal microscopy was used to detect PrPC localization in an N2a neuroblastoma cell line 
after a 24hr treatment with 100 µM of each compound, while CuSO4 and glycine was used as a positive 
control for internalization.  
 
 
